Merck Manual

Please confirm that you are a health care professional

honeypot link

Hepatitis C, Acute

By

Sonal Kumar

, MD, MPH, Weill Cornell Medical College

Reviewed/Revised Aug 2022 | Modified Sep 2022
View PATIENT EDUCATION
Topic Resources

Hepatitis C is caused by an RNA virus that is often parenterally transmitted. It sometimes causes typical symptoms of viral hepatitis, including anorexia, malaise, and jaundice but may be asymptomatic. Fulminant hepatitis and death rarely occur. Chronic hepatitis develops in about 75% and can lead to cirrhosis and rarely hepatocellular carcinoma. Diagnosis is by serologic testing. Treatment is with antiviral drugs. No vaccine is available.

In the US, 4136 cases of acute hepatitis C infection were reported in 2019. However, because many cases are not recognized or not reported, the Centers for Disease Control and Prevention (CDC) estimates that the actual number of new infections was 57,500 in 2019 (1 General reference Hepatitis C is caused by an RNA virus that is often parenterally transmitted. It sometimes causes typical symptoms of viral hepatitis, including anorexia, malaise, and jaundice but may be asymptomatic... read more ). The number of acute hepatitis C cases has been rising in the United States since 2013.

Hepatitis C virus (HCV) is a single-stranded RNA flavivirus that causes acute viral hepatitis Overview of Acute Viral Hepatitis Acute viral hepatitis is diffuse liver inflammation caused by specific hepatotropic viruses that have diverse modes of transmission and epidemiologies. A nonspecific viral prodrome is followed... read more and is a common cause of chronic viral hepatitis Overview of Chronic Hepatitis Chronic hepatitis is hepatitis that lasts > 6 months. Common causes include hepatitis B and C viruses, nonalcoholic steatohepatitis (NASH), alcohol-related liver disease, and autoimmune liver... read more . Six major HCV subtypes exist with varying amino acid sequences (genotypes); these subtypes vary geographically and in virulence and response to therapy. HCV can also alter its amino acid pattern over time in an infected person, producing quasispecies.

HCV infection sometimes occurs simultaneously with specific systemic disorders, including the following:

The mechanisms are uncertain.

Up to 20% of patients with alcoholic liver disease Alcohol-Related Liver Disease Alcohol consumption is high in most Western countries. According to a survey using the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) definition of alcohol... read more Alcohol-Related Liver Disease harbor HCV. The reasons for this high association are unclear because concomitant alcohol and drug use accounts for only a portion of cases. In these patients, HCV and alcohol act synergistically to worsen liver inflammation and fibrosis.

Transmission of hepatitis C

Infection is most commonly transmitted through blood, primarily when parenteral drug users share needles, but also through sharing vessels for intranasal drug use, or tattoos or body piercing with nonsterile equipment.

Sexual transmission and vertical transmission of hepatitis C from mother to infant are relatively rare.

Transmission of hepatitis C through blood transfusion has become very rare since the advent of screening tests for donated blood.

Some sporadic cases occur in patients without apparent risk factors.

HCV prevalence varies with geography and other risk factors.

General reference

Symptoms and Signs of Acute Hepatitis C

Hepatitis C may be asymptomatic during the acute infection. Its severity often fluctuates, sometimes with recrudescent hepatitis and roller-coaster aminotransferase levels for many years or even decades. Fulminant hepatitis Fulminant Hepatitis Fulminant hepatitis is a rare syndrome of rapid (usually within days or weeks), massive necrosis of liver parenchyma and a decrease in liver size (acute yellow atrophy); it usually occurs after... read more is extremely rare.

Diagnosis of Acute Hepatitis C

  • Serologic testing

  • HCV RNA measurement

If acute viral hepatitis is suspected, the following tests are done to screen for hepatitis viruses A, B, and C:

  • IgM antibody to hepatitis A virus (IgM anti-HAV)

  • Hepatitis B surface antigen (HBsAg)

  • IgM antibody to hepatitis B core (IgM anti-HBc)

  • Antibody to HCV (anti-HCV) and HCV RNA

If the anti-HCV test is positive, HCV RNA is measured to distinguish active from past hepatitis C infection (see table Hepatitis C Serology Hepatitis C Serology Hepatitis C Serology ).

In hepatitis C, serum anti-HCV represents chronic, past, or acute infection; the antibody is not protective. When cases are unclear or when suspicion for hepatitis C is high, HCV RNA is measured. Anti-HCV usually appears within 2 weeks of acute infection but is sometimes delayed; however, HCV RNA is positive sooner.

Table

Other tests

Liver tests are needed if not previously done; they include serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase.

Other tests should be done to evaluate liver function and disease severity; they include serum albumin, bilirubin, platelet count, and prothrombin time/international normalized ratio (PT/INR).

Treatment of Acute Hepatitis C

  • Antiviral therapy

There are a number of highly effective direct-acting antiviral drugs Overview of HCV treatment (DAAs) for hepatitis C that may decrease the likelihood of developing chronic infection. DAAs also help prevent transmission to others. Current recommendations are to start treatment after the initial diagnosis of acute HCV, without waiting for spontaneous resolution.

Alcohol and hepatotoxic drugs (eg, acetaminophen) should be avoided because it can increase liver damage. Restrictions on diet or activity, including commonly prescribed bed rest, have no scientific basis.

Viral hepatitis should be reported to the local or state health department.

Treatment reference

Prevention of Acute Hepatitis C

Patients should be advised to avoid high-risk behavior (eg, sharing needles to inject drugs, getting tattoos and body piercings).

Blood and other body fluids (eg, saliva, semen) are considered infectious. Risk of infection after a single needlestick exposure is about 1.8%. Barrier protection is recommended, but isolation of patients is of no value in preventing acute hepatitis C.

Risk of transmission from HCV-infected medical personnel appears to be low, and there are no CDC recommendations to restrict health care workers with hepatitis C infection from working.

Posttransfusion infection is minimized by avoiding unnecessary transfusions and screening all donors for hepatitis B and C. Screening has decreased the incidence of posttransfusion hepatitis B and hepatitis C, which are now extremely rare in the US.

No product exists for immunoprophylaxis of HCV. The propensity of HCV for changing its genome hampers vaccine development.

Preexposure or postexposure prophylaxis with antiviral therapy is not recommended.

Key Points

  • Hepatitis C is usually transmitted by parenteral contact with contaminated blood; transmission from mucosal contact with other body fluids and perinatal transmission from infected mothers are rare.

  • About 75% of patients with acute hepatitis C develop chronic hepatitis C, which leads to cirrhosis in 20 to 30%; some patients with cirrhosis develop hepatocellular carcinoma.

  • Diagnose by testing for antibody to HCV and HCV RNA.

  • Treat with antiviral drugs after initial diagnosis of hepatitis C, without waiting for spontaneous resolution.

  • There is no vaccine for hepatitis C.

More Information

The following English-language resource may be useful. Please note that THE MANUAL is not responsible for the content of this resource.

  • Centers for Disease Control and Prevention (CDC): Viral Hepatitis: Hepatitis C questions and answers for health professionals: This resource provides an overview of hepatitis C (including definitions, statistics, risk factors, and complications) and information about transmission, symptoms, diagnosis, and treatment, as well as hepatitis C and pregnancy. Accessed July 6, 2022.

Drugs Mentioned In This Article

Drug Name Select Trade
Albuked , Albumarc, Albuminar, Albuminex, AlbuRx , Albutein, Buminate, Flexbumin, Kedbumin, Macrotec, Plasbumin, Plasbumin-20
7T Gummy ES, Acephen, Aceta, Actamin, Adult Pain Relief, Anacin Aspirin Free, Apra, Children's Acetaminophen, Children's Pain & Fever , Comtrex Sore Throat Relief, ED-APAP, ElixSure Fever/Pain, Feverall, Genapap, Genebs, Goody's Back & Body Pain, Infantaire, Infants' Acetaminophen, LIQUID PAIN RELIEF, Little Fevers, Little Remedies Infant Fever + Pain Reliever, Mapap, Mapap Arthritis Pain, Mapap Infants, Mapap Junior, M-PAP, Nortemp, Ofirmev, Pain & Fever , Pain and Fever , PAIN RELIEF , PAIN RELIEF Extra Strength, Panadol, PediaCare Children's Fever Reducer/Pain Reliever, PediaCare Children's Smooth Metls Fever Reducer/Pain Reliever, PediaCare Infant's Fever Reducer/Pain Reliever, Pediaphen, PHARBETOL, Plus PHARMA, Q-Pap, Q-Pap Extra Strength, Silapap, Triaminic Fever Reducer and Pain Reliever, Triaminic Infant Fever Reducer and Pain Reliever, Tylenol, Tylenol 8 Hour, Tylenol 8 Hour Arthritis Pain, Tylenol 8 Hour Muscle Aches & Pain, Tylenol Arthritis Pain, Tylenol Children's, Tylenol Children's Pain+Fever, Tylenol CrushableTablet, Tylenol Extra Strength, Tylenol Infants', Tylenol Infants Pain + Fever, Tylenol Junior Strength, Tylenol Pain + Fever, Tylenol Regular Strength, Tylenol Sore Throat, XS No Aspirin, XS Pain Reliever
View PATIENT EDUCATION
NOTE: This is the Professional Version. CONSUMERS: View Consumer Version
quiz link

Test your knowledge

Take a Quiz! 
iOS ANDROID
iOS ANDROID
iOS ANDROID
TOP